{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-038705","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.350639+00:00","generated_at":"2026-06-04T07:57:20.480482+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Replimune names Sushil Patel CEO effective April 1; Astley-Sparke becomes Executive Chairman","bullets":["Dr. Sushil Patel appointed CEO effective April 1, 2024; previously Chief Strategy Officer.","Philip Astley-Sparke transitions from CEO to Executive Chairman; Dieter Weinand becomes Lead Independent Director.","Robert Coffin moves to Founder & Chief Scientist advisory role; Paul Bullock promoted to Chief Manufacturing Officer.","Colin Love (COO) retiring May 31; Pamela Esposito and Tanya Lewis leave executive roles but remain advisors.","Company on track to submit RP1 BLA in 2H 2024 for anti-PD1 failed melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-038705","json":"https://secwatch.observer/filing/0001104659-24-038705.json","markdown":"https://secwatch.observer/filing/0001104659-24-038705.md","text":"https://secwatch.observer/filing/0001104659-24-038705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/tm249769d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:57:20.480482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06b87daf33","claim":"Paul Bullock changed role as chief manufacturing officer at Replimune Group, Inc..","evidence_excerpt":"Paul Bullock, the Company’s current senior vice president, operations and Framingham site head, is being promoted to the Company’s chief manufacturing officer effective April 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"chief manufacturing officer"}],"fact_type":"executive_change"},{"claim_id":"4cb2499b12","claim":"Dr. Sushil Patel was appointed as chief executive officer at Replimune Group, Inc..","evidence_excerpt":"Dr. Sushil Patel, the Company’s current chief strategy officer, has been appointed as the Company’s chief executive officer, effective as of April 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"chief executive officer"}],"fact_type":"executive_change"},{"claim_id":"768375706d","claim":"Dieter Weinand changed role as lead independent director of the Board at Replimune Group, Inc..","evidence_excerpt":"Dieter Weinand, the Company’s current chair of the Board, will transition into the newly created role of the lead independent director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"lead independent director of the Board"}],"fact_type":"executive_change"},{"claim_id":"85a6e1fd63","claim":"Tanya Lewis changed role as advisor at Replimune Group, Inc..","evidence_excerpt":"Tanya Lewis, the Company’s current chief development operations officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"left executive position"},{"label":"Role","value":"advisor"}],"fact_type":"executive_change"},{"claim_id":"baa777094f","claim":"Philip Astley-Sparke changed role as executive chairman of the Board at Replimune Group, Inc..","evidence_excerpt":"Philip Astley-Sparke, the Company’s current chief executive officer, will transition to the role of executive chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"executive chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"d621e943a1","claim":"Dr. Colin Love retired as chief operating officer at Replimune Group, Inc..","evidence_excerpt":"Dr. Colin Love, the Company’s current chief operating officer, will retire from the Company, effective May 31, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"chief operating officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}